ArticleEpidemiology and infection2017
Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims.
Article in Epidemiology and infection, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06286007 (Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases.Human vaccines & immunotherapeutics · 2023Pooled it
- Adult pertussis in the acellular-cell vaccine era: Comparative analysis of pertussis toxin antibodies in hospitalized patients with prolonged cough.Human vaccines & immunotherapeutics · 2025Article
- A budget impact analysis of adult immunization with tetanus, diphtheria, and pertussis vaccination for the prevention of pertussis in at-risk populations in Colombia.Human vaccines & immunotherapeutics · 2025Article
- The Burden of Pertussis Disease and Vaccination Coverage in Australian Adults Attending Primary Health Care.Vaccines · 2025Article
- Review
- Seroprevalence ofERJ open research · 2025Article
- Review
- Public health management of pertussis in adults: Practical challenges and future strategies.Human vaccines & immunotherapeutics · 2024Review
- Understanding the impact of adult pertussis and current approaches to vaccination: A narrative review and expert panel recommendations.Human vaccines & immunotherapeutics · 2024Review
- Pertussis vaccination in adults: a behavioral study of physicians from the US, France, and Germany.BMC primary care · 2024Article
- Review
- Epidemiology of Pertussis and Pertussis-Related Complications in Adults: A German Claims Data Analysis.Infectious diseases and therapy · 2024Article
- Population-Based Study of Pertussis Incidence and Risk Factors among Persons >50 Years of Age, Australia.Emerging infectious diseases · 2024Observational
- Estimating the pertussis burden in adolescents and adults in the United States between 2007 and 2019.Human vaccines & immunotherapeutics · 2023Article
- Burden of Pertussis in Adults Aged 50 Years and Older: A Retrospective Database Study in England.Infectious diseases and therapy · 2023Article
- Risk Factors of Pertussis Among Older Adults in South Korea: A Nationwide Health Data-Based Case-Control Study.Infectious diseases and therapy · 2023Article
- Burden of Pertussis in Individuals with a Diagnosis of Asthma: A Retrospective Database Study in England.Journal of asthma and allergy · 2022Article
- Improving vaccination rates in older adults and at-risk groups: focus on pertussis.Aging clinical and experimental research · 2022Review
- Recommendations of the Italian society for infectious and tropical diseases (SIMIT) for adult vaccinations.Human vaccines & immunotherapeutics · 2021Article
- Pertussis in Individuals with Co-morbidities: A Systematic Review.Infectious diseases and therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individuals with chronic respiratory conditions may be at increased risk for pertussis. We conducted a retrospective administrative claims analysis to examine the incidence and economic burden of diagnosed pertussis among adolescents and adults in the USA with chronic obstructive pulmonary disease (COPD) or asthma. Patients aged ⩾11 years with diagnosed pertussis and pre-existing COPD (n = 343) or asthma (n = 1041) were matched 1:1 to patients with diagnosed pertussis but without COPD or asthma. Differences in all-cause costs ('excess' costs) during the 45-day and 3-month and 6-month periods before and after the pertussis index date were calculated; adjusted excess costs were estimated via multivariate regressions. The incidence of diagnosed pertussis was higher among patients with COPD or asthma than among matched patients. Compared with matched patients, patients with pertussis and pre-existing COPD or asthma accrued greater all-cause adjusted costs across study periods ($3694 and $1193 more, respectively, in the 45-day period; $4173 and $1301 more in the 3-month period; and $6154 and $1639 more in the 6-month period; all P < 0·0001). Patients with pre-existing COPD or asthma experience an increased economic burden after diagnosed pertussis and may especially benefit from targeted tetanus, diphtheria, and acellular pertussis vaccination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.